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ABSTRACT   Unresectable, metastatic, recurrent gastrointestinal stromal tumor (GIST) is 
primarily treated with a molecular-targeted therapeutic agent, imatinib. However, after an 
initial response, a secondary resistance to the drug often occurs after a few years. We report 
here a case of a resected giant GIST of the jejunum that disseminated following treatment 
with imatinib. A 59-year-old male presented with a giant tumor in the abdominal cavity, which 
was diagnosed as GIST by needle biopsy; he was administered 400 mg/day imatinib. Eight 
months later, the tumor had considerably decreased, but multiple tumors in small intestine and 
mesenterium, indicating dissemination, appeared. Administration of imatinib was continued 
for 36 months from the initial treatment and the dissemination gradually reduced and almost 
disappeared except for a tumor in the right upper abdomen. Three years later, follow-up 
computed tomography revealed that the disseminated lesions had enlarged; a part of the 
intrapelvic tumor was suspected to be viable. We deduced that the tumor developed partial 
resistance to imatinib: therefore, we surgically removed as many disseminated tumors as 
possible. Pathologically, resected tumors appeared to have no viable tumor cells except for a 
small part of the primary tumor in which mitosis was 0-1/50 high-power fields. Genetic analysis 
of surgically resected specimen for c-kit mutation revealed an exon 11 c554-559 deletion. 
   17 months after operation, another disseminated tumor was detected. Imaninib therapy was 
re-introduced. The dissemination was diminished after three months re-challenged imatinib and 
continues to be recurrence-free for two years. When partial resistance to imatinib is observed, 
combined modality therapy that involves chemotherapy with surgical intervention at early stages 
is expected to improve the outcome. doi：10.11482/KMJ-E43(1)5　(Accepted on January 11, 2017)
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INTRODUCTION
   Gastrointestinal stromal tumors (GIST) are 
specific, generally Kit (CD117)-positive and Kit 
or platelet-derived growth factor receptor alpha 
(PDGFRA) mutation-driven mesenchymal tumors 
of the gastorointestinal tract. Imatinib mesylate 
(Glivec®, Novartis Pharma, Switzerland), a selective 
inhibitor of BCR-ABL tyrosine kinase and KIT and 
PDGFRA tyrosine kinases, has become the standard 
therapy for advanced/metastatic GISTs worldwide.
   However, following an initial response, a secondary 
resistance to the drug occurs at a median time of 
two years following the initiation of treatment and 
affects most patients after four years. Therefore, 
additional therapy including surgery is essential.
   Here we report a case of a resected giant GIST of 
the jejunum that disseminated following treatment 
with imatinib, for considering multimodal therapy 
that combines adjuvant surgery and molecular-
targeted agent. 
CASE REPORT
   A 59-years-old male consulted his family doctor 
for a two month history of lower abdominal mass in 
July 2007. Laboratory tests showed no abnormalities 
including tumor markers. Abdominal computed 
tomography (CT) images revealed a giant tumor, 
210×120×200 mm in size, in the abdominal 
cavity (Fig. 1). Following transabdominal wall 
needle biopsy at the hospital, the tumor cells were 
strongly positive for the c-Kit oncogene, positive 
for Actin and negative for S100 protein and CD34; 
thus, GIST was diagnosed. The patient was referred 
to a hospital in Tokyo by his personal reason and 
admitted to the hospital. Administration of 400 
mg/day imatinib, which continued for 36 months 
from the initial treatment, was initiated to confirm 
the diagnosis; five months later he was referred to 
Okayama University hospital. Eight months after 
initiating the treatment, CT showed that the tumor 
had considerably decreased in size, 130×110×
110 mm (Fig. 2) but revealed multiple tumors in 
the small intestine and mesenterium, indicating 
dissemination. Administration of imatinib was 
continued and the main tumor has not changed 
in size since that time but the maximum standard 
Fig 1
Fig. 1.　Abdominal CT images reveled a giant tumor 210×120×200 mm in size in the abdominal cavity.
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uptake value (SUV) from 18-FDG PET scans of 
the main tumor was less than 2.5 in May 2008. The 
dissemination gradually diminished thereafter and 
almost disappeared except for a tumor in the right 
upper abdomen (Fig. 3). We deduced the effect of 
imatinib was a partial response, and we continued Fig 2
Fig. 2.　CT showed that the tumor had shrunk remarkably to 130×110×110 mm in size.
Fig 3
Fig. 3.　Three years later, follow-up CT showed multiple disseminated lesions (white arrows) and a part of 
the intrapelvic primary tumor was suspected to be viable.
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its administration.
   Three years after initiating the treatment, follow-
up CT demonstrated that the multiple disseminated 
lesions, and a part of the intrapelvic tumor was 
suspected to be viable (Fig. 3). We concluded 
that the tumor had developed partial resistance to 
imatinib. We surgically resected the tumor, which 
was the size of a child’s head and had developed 
within the jejunum approximately 200 mm at the 
back of Treitz’ ligament, along with a small part of 
jejunum. In addition, several tumors 5-30 mm in 
size were observed throughout the intra-abdominal 
mesenterium and peritoneum. We surgically 
removed as many of these tumors as possible (Fig. 
4), but the tumors less than 5 mm in size were 
abandoned. 
   Pathologically, most tumors showed hyalinization/
edematous change/necrosis/apoplexy lesions, and 
Fig 4
Fig. 4.　The primary tumor, 125 mm in diameter, and disseminated tumors of 5-30 mm in size were resected.
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Fig. 5.　Pathological findings: Most tumors showed hyalinization/edematous change/
necrosis/apoplexy lesions. Viable tumor cells remained in a small part of primary tumor, in 
which mitosis (black arrow) was 0-1/50 HPFs. H&E ×200.
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no viable tumor cells were found except those in a 
small part of the primary tumor, in which mitosis 
was 0-1/50 high power fields (HPFs) (Fig. 5). 
Immunostaining revealed that the tumor cells 
were positive for CD34 (Fig. 6a), c-kit (Fig. 6b) 
and α-smooth muscle actin (SMA) (Fig. 6c) and 
negative for S100 and p53. MIB-1 index, also 
known as labeling index positive for Ki-67 and 
proliferation -related antigen, was approximately 
5% (Fig. 6d). Genetic analysis of surgically resected 
specimen for the c-kit mutation revealed an exon 11 
c554-559 deletion.
   However, 17 months after operation, another 
disseminated tumor was detected by follow-up CT 
(Fig.7a). Imaninib therapy (400mg/day) was re-
introduced. The dissemination was diminished 
after three months re-challenged imatinib therapy 
(Fig.7b). The patient continues to be recurrence-free 
for two years since re-challenged imatinib.
DISCUSSION
   The efficacy of imatinib for the treatment of 
unresectable, metastatic, recurrent GIST has been 
established, and imatinib is considered to be the 
drug of choice１，２）. However, approximately 12%-
14% of GIST patients treated with imatinib, showed 
no effect after the initiation of treatment (primary 
resistance), and half of the patients who initially 
respond developed resistance (secondary resistance) 
after receiving the treatment for approximately two 
years. Thus, cases of radical cure are extremely 
rare３）. In addition, continuous administration may 
be impossible in some patients because of adverse 
effects.
   Two paths of action can be considered for 
imatinib-resistant GIST: (1) increased dosage of 
imatinib, and (2) change to sunitinib. However, 
sunitinib tends to be ineffective to tumor cells which 
possessed mutations on exon17 or 18, which is 
the activation loop domain, and its efficacy in the 
a b
c d
Fig 6
Fig. 6.　Immunohistochemical features of the tumor.
(a) CD34 was positive in the tumor cells. Immunostaining ×200 (b) c-kit was positive in the tumor cells. 
Immunostaining ×200 (c) α-SMA was positive in the tumor cells. Immunostaining ×200 (d) The MIB-1 
index of the tumor was approximately 5%.
10 Kawasaki Medical Journal
Fig 7a
a
Fig. 7.　(a) 17 months after operation, another disseminated tumors (white arrows) was detected by follow-up 
CT. (b)The dissemination was diminished after three months re-chalenged imatinib therapy.
Fig 7b
b
treatment of imatinib-resistant GIST shows a clinical 
benefit response (CBR) of 53% and an intermediate 
PFS value of approximately 34 weeks４）, which 
makes it inefficient. We believe that resectable 
partially-resistant GIST should be surgically 
resected to preserve sunitinib as a future alternative. 
The 2009 National Comprehensive Cancer Network 
(NCCN) guidelines state that, if unresectable, 
metastatic, recurrent GIST can be controlled by 
administration of imatinib, surgical intervention 
should be considered at an appropriate time. Bauer 
et al. also reported that if administration of imatinib 
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can control unresectable, metastatic GIST, surgical 
intervention tends to extend the survival period to 
a greater degree than continued therapy with solely 
imatinib５）. At the American Society of Clinical 
Oncology (ASCO) in 2010, Nguyen et al. reported 
a better prognosis for patients whose metastatic 
GIST was, in principle, treated with imatinib 
followed by surgical intervention. According 
to Ford SJ et al.６）, surgery may have a limited 
favorable impact on progression-free survival and 
overall survival for those patients whose disease 
is responding to imatinib or those with limited 
focal progression. Patients with imatinib resistant 
disease should not be offered surgery unless as an 
emergency where palliative intervention may be 
justified６）. Furthermore, a randomized comparison 
study (EORTC 62063) is currently being conducted 
in Europe and Australia to review the utility of 
surgical intervention in patients with metastatic, 
recurrent GIST controlled by imatinib therapy. 
With regard to the timing of surgical intervention, a 
retrospective study by Mussi et al. in unresectable, 
recurrent, metastatic, GIST patients treated with 
imatinib revealed that surgery performed when 
the best clinical response was obtained yielded a 
significantly better two years- progression-free 
survival (PFS) and five years- disease-specific 
survival (DSS) than surgery conducted when local 
progression had already been diagnosed７）. 
   A single- facility retrospective study of patients 
with unresectable, metastatic GIST conducted in the 
USA showed a significantly better prognosis when 
resection of the residual tumor was performed under 
the control of tyrosine kinase inhibitory agents, such 
as imatinib, compared with surgical intervention at 
an aggravated stage８）. In other words, if surgical 
resection is performed on the GIST during the 
efficacious stage when imatinib resistance emerges 
or in the early stages of partial resistance, an 
excellent prognosis may be obtained, such as in the 
patient described here. Thus, the efficacy of imatinib 
in the treatment of GIST and the early discovery of 
resistance are considered to be important factors in 
its prognosis.
   Generally, the efficacy of treatment of a solid 
tumor is assessed on the basis of RECIST criteria, 
and more than 30% reduction in tumor diameter is 
judged to be a partial response. However, a change 
in CT value in GIST due to reduced blood flow or 
cystic changes of the tumor is known to reflect a 
treatment effect. Therefore, to evaluate the efficacy 
of imatinib in the treatment of GIST, Choi criteria 
that included tumor diameter and changes in CT 
value have been used９）. Furthermore, 18FDG-
PET enables the evaluation of viable cells in GIST 
by identifying metabolic changes in the tumors. 
Stroobants et al.10） and Antoch et al.11） reported 
that, after the administration of imatinib, changes in 
uptake in PET are a good reflection of a treatment 
effect and is well correlated with prognosis in GIST. 
In our patient, reduction in tumor diameter stopped 
8 months after the onset of administration of 
imatinib; however, the SUV value was as low as 2.5. 
Therefore, administration of imatinib was continued 
and a reduction in disseminated lesion was observed 
for 3 years. Furthermore, Gayed et al.12） reported 
that PET-CT was useful in assessment of the effect 
of imatinib on recurrent GIST; therefore, PET-CT 
is believed to be valuable in the early evaluation of 
resistance to imatinib in unresectable, metastatic, 
recurrent GIST. 
   Unresectable, metastatic, recurrent GIST 
is primarily treated with molecular-targeted 
therapeutic agents, such as imatinib and adjuvant 
surgery, if the tumor became resectable, is one of the 
most effective therapeutic strategies. Even when the 
partial resistance to imatinib is observed, combined 
modality therapy that involves surgical intervention 
is expected to improve the treatment outcome.
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